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Abstract
The design and synthesis of a multivalent gold nanoparticle therapeutic is presented. SDC-1721, a
fragment of the potent HIV inhibitor TAK-779, was synthesized and conjugated to 2.0 nm
diameter gold nanoparticles. Free SDC-1721 had no inhibitory effect on HIV infection; however,
the (SDC-1721)-gold nanoparticle conjugates displayed activity comparable to that of TAK-779.
This result suggests that multivalent presentation of small molecules on gold nanoparticle surfaces
can convert inactive drugs into potent therapeutics.
It has been suggested that biological systems exploit multivalency in the synthesis of high-
affinity ligands because they allow an organism to take advantage of an existing set of
monovalent ligands without the need for evolving completely new molecules for every
required function.1 Multivalent displays are ubiquitous in biology and can confer
dramatically enhanced affinity. For example, binding between multiple hemagglutinin (HA)
ligands of an influenza virus and sialic acid (SA) surface receptors of an erythrocyte during
viral infection is estimated to occur with an affinity of 1013 M−1, while the association
constant for a single SA–HA interaction is 103 M−1.1
In the development of therapeutics, a multivalent binding strategy could offer many
advantages. Synthetic systems that present multiple low-affinity biomolecule binding
ligands may prove to be more synthetically accessible and could allow one to tune binding
affinity over several orders of magnitude. Moreover, nanoparticles that are comparable in
size to proteins and present multiple protein-binding ligands may be effective at disrupting
protein/protein interactions that drive disease pathogenesis. Multivalent linear polymers,
dendrimers, proteins, and liposomes have successfully targeted pathogenic biomolecule
targets.1,2 Of particular note are SA-coated liposomes and dendrimers that bind to HA on
the surface of an influenza virus with affinity enhancements of 102–106.1
Particle-based displays of multiple ligands have the additional advantage of creating a high
local concentration of binding molecules. Consequently, binding equilibrium between a
surface-bound ligand and receptor favors formation of more ligand-receptor pairs. For
instance, DNA hybridization is thermodynamically favored by 1 order of magnitude if one
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of the single-stranded DNA sequences is conjugated to a 10 nm diameter gold nanoparticle
surface.3,4
The advantages of multivalent therapeutics are illustrated here with the demonstration that
gold nanoparticles transform a weakly binding and biologically inactive small molecule into
a multivalent conjugate that effectively inhibits HIV-1 fusion to human T cells. We
employed 2.0 nm diameter, mercaptobenzoic acid modified gold particles as a nanoscale
platform to construct our multivalent therapeutic. These particles have a proposed empirical
formula of [Au144(SC6H4COOH)52] and are related to the [Au102(SC6H4-COOH)44]
monolayer-protected gold nanoparticles that were recently characterized by X-ray
crystallography.5 Importantly, this class of gold particles is similar to proteins and
dendrimers in that they are atomically precise and monodisperse nanoscale molecules.
The 2.0 nm diameter mercaptobenzoic acid coated gold nano-particles were conjugated to
SDC-1721, a derivative of TAK-779, a known CCR5 antagonist (Figure 1). CCR5 serves as
the principal entry co-receptor for most commonly transmitted strains of HIV-1 and those
that predominate in the early years of infection.6 A significant amount of structure–activity
relationship (SAR) data has been generated with regard to TAK-779, most notably that the
quaternary ammonium salt is essential for high-affinity binding and effective inhibition of
HIV fusion. TAK-779 homologues that lack this quaternary ammonium salt are devoid of
activity.7 Unfortunately, the quaternary ammonium salt imbues TAK-779 with poor
pharmacological properties, such as significant irritation at the injection site, which led to an
exhaustive search for alternate small molecule CCR5 antagonists.7 As an alternative
approach and proof-of-concept, we synthesized SDC-1721, a TAK-779 homologue that
lacks the quaternary ammonium salt moiety, to show that it is possible to conjugate a low-
affinity, biologically inactive small molecule to a gold nanoparticle to create biologically
active multivalent gold nanoparticle therapeutics. The ability to transform small molecules
that are not therapeutically viable into potential therapeutics by simply conjugating them to a
gold nanoparticle scaffold could greatly accelerate the discovery of effective new drug
formulations.
SDC-1721 was synthesized (Supporting Information) using a modification of the synthetic
approach to TAK-7798 and coupled to the 2.0 nm diameter gold nanoparticles via a simple
ligand exchange reaction. The average number of SDC-1721 molecules per particle was
determined to be 12, and the particle size was verified by transmission electron microscopy.
Examination of the micrographs revealed no substantial differences in core size or
dispersion when compared to the 2.0 nm diameter gold nanoparticles prior to ligand
exchange.
To evaluate the antiviral activity of the nanoparticle conjugate, phytohemagglutinin (PHA)-
stimulated peripheral blood mono-nuclear cells (PBMCs) were infected with the CCR5-
tropic HIV-1 clone JR-CSF in the presence or absence of the test compounds. On day 7
postinfection, supernatants were collected and HIV-1 capsid p24 antigen was measured by
ELISA. As shown in Figure 2a, TAK-779 inhibited HIV-1 replication with an IC50 of 10
nM. The IC50 for TAK-779 against four different CCR5-tropic viral isolates ranged from 1.6
to 3.7 nM.9 However, JR-CSF was not one of the viruses tested. With a similar virus, JR-FL,
TAK-779 revealed an IC50 of 20 nM.10 Sensitivity to CCR5 entry inhibitors is impacted by
receptor expression levels and HIV-1 envelope/receptor affinity, mediated by both cellular
and viral determinants.11 Thus, JR-CSF appears to be inherently less sensitive to TAK-779.
We next tested whether, as had been reported, the quaternary ammonium group was
essential to TAK-779 activity.7 SDC-1721 did not inhibit viral replication (Figure 2b).
Conjugation of SDC-1721 ((SDC-1721)–NP) to gold nanoparticles at an average ratio of
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12:1 restored activity with an IC50 of 10 nM (Figure 2c). To ensure that the inhibitory effect
was not due to the gold particle, a glutathione-modified gold nanoparticle (GSH–NP) control
was tested. The GSH–NP is unable to inhibit viral replication (Figure 2d). In addition, we
verified that multivalent display of SDC-1721 on the nanoparticle surface was required for
activity by assaying (SDC-1721)–NP conjugates with an average ratio of 0.93/1. This
nanoparticle preparation was unable to inhibit viral replication up to 300 μM (Supporting
Information). There was no difference in cell viability between samples at these
concentrations.
We further verified that inhibition of viral replication was specific for viral entry. This was
assayed by performing single-cycle infection experiments using the TZM-bl luciferase
reporter gene assay system.12 This cell line is engineered to express high levels of CCR5
and CD4 and contains a luciferase reporter gene under control of the HIV-1 promoter, which
is inducible in trans by the viral protein Tat.13 TZM-bl cells were infected with JR-CSF in
the presence or absence of the test compounds. Forty-eight hour postinfection, luciferase
activity was measured as relative luminescence units (RLU). SDC-1721-modified gold
nanoparticles inhibited viral entry as well as TAK-779 (Figure 2e). At 48 h, viral production
is insignificant, thus establishing inhibition of viral replication at the stage of viral entry.
In conclusion, we have documented the first application of small-molecule coated gold
nanoparticles as effective inhibitors of HIV fusion. The results presented here demonstrate
that therapeutically inactive monovalent small organic molecules may be converted into
highly active drugs by simply conjugating them to gold nanoparticles.
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(A–D) Multiple-cycle inhibition assays. (A) TAK-779 HIV-1 inhibition; (B) SDC-1721
HIV-1 inhibition; (C) (SDC-1721)–NP HIV-1 inhibition; (D) GSH–NP HIV-1 inhibition;
(E) single-cycle HIV-1 infectivity inhibition with TAK-779 and (SDC-1721)–NP.
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